{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:21:28Z","timestamp":1782955288944,"version":"3.54.5"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Type 1 diabetes mellitus (T1DM) requires lifelong basal and bolus insulin therapy to maintain glycemic control, often necessitating multiple daily injections. Recently, the development of once-weekly basal insulin formulations, insulin icodec and insulin efsitora alfa, has introduced the possibility of reducing injection burden while preserving efficacy. This review evaluates the pharmacological properties, clinical trial data, patient considerations, and regulatory landscape of these novel therapies to determine their potential role in T1DM management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Insulin icodec and insulin efsitora alfa utilize distinct structural modifications to extend their duration of action, allowing for weekly dosing. Insulin icodec achieves prolonged activity through enhanced albumin binding and reduced insulin receptor affinity, while insulin efsitora alfa utilizes Fc-fusion technology and neonatal Fc receptor recycling. Phase 3 trials (the ONWARDS-6 trial for insulin icodec and the QWINT-5 trial for insulin efsitora), demonstrated that both insulins achieved glycemic control comparable to that provided by once-daily basal insulin degludec. However, both formulations were associated with a higher incidence of hypoglycemia, particularly during the titration period. Additionally, patient-reported outcomes varied, with insulin efsitora being associated with greater treatment satisfaction than insulin icodec.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Once-weekly basal insulin represents a potential paradigm shift in T1DM management, offering convenience but presenting challenges related to hypoglycemia risk, patient acceptance, and regulatory hurdles. Further research is needed to refine titration protocols, identify optimal patient populations, and address safety concerns before these therapies can become standard of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf169","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:02:52Z","timestamp":1751011372000},"page":"1220-1227","source":"Crossref","is-referenced-by-count":2,"title":["Once-weekly basal insulin therapy in type 1 diabetes: A paradigm shift or a work in progress?"],"prefix":"10.1093","volume":"82","author":[{"given":"Mackenzi","family":"Meier","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, South University School of Pharmacy , Savannah, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakese","family":"Hagans","sequence":"additional","affiliation":[{"name":"South University School of Pharmacy , Savannah, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brackett","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, South University School of Pharmacy , Savannah, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2025110902541231800_zxaf169-B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1179551419844521","article-title":"Therapies for type 1 diabetes: current scenario and future perspectives","volume":"12","author":"Pathak","year":"2019","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"5","key":"2025110902541231800_zxaf169-B2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/dom.15510","article-title":"Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes","volume":"26","author":"H\u00f6velmann","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"10458","key":"2025110902541231800_zxaf169-B3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(24)01804-X","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial","volume":"404","author":"Bergenstal","year":"2024","journal-title":"Lancet"},{"issue":"10413","key":"2025110902541231800_zxaf169-B4","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0140-6736(23)02179-7","article-title":"Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial","volume":"402","author":"Russell-Jones","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"2025110902541231800_zxaf169-B5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/jdi.14384","article-title":"Pharmacological characteristics of once-weekly insulin icodec in Japanese individuals with type 1 diabetes","volume":"16","author":"Eto","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2025110902541231800_zxaf169-B6","doi-asserted-by":"publisher","first-page":"e002301","DOI":"10.1136\/bmjdrc-2021-002301","article-title":"Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing","volume":"9","author":"Nishimura","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025110902541231800_zxaf169-B7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/DMSO.S421527","article-title":"Research advances in fusion protein-based drugs for diabetes treatment","volume":"17","author":"Deng","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"2025110902541231800_zxaf169-B8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"issue":"1","key":"2025110902541231800_zxaf169-B9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","article-title":"Strategies for extending the half-life of biotherapeutics: successes and complications","volume":"25","author":"Binder","year":"2025","journal-title":"Exp Opin Biol Ther"},{"key":"2025110902541231800_zxaf169-B10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2025110902541231800_zxaf169-B11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/endrev\/bnad037","article-title":"The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa","volume":"45","author":"Rosenstock","year":"2024","journal-title":"Endocr Rev"},{"issue":"49","key":"2025110902541231800_zxaf169-B12","doi-asserted-by":"publisher","first-page":"17861","DOI":"10.1021\/jacs.7b08465","article-title":"Light control of protein solubility through isoelectric point modulation","volume":"139","author":"Nadendla","year":"2017","journal-title":"J Am Chem Soc"},{"issue":"suppl 1","key":"2025110902541231800_zxaf169-B13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0889-8529(07)80004-1","article-title":"Pharmacology of insulin detemir","volume":"36","author":"Kurtzhals","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2025110902541231800_zxaf169-B14","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.1016\/j.molmet.2021.101325","article-title":"Structural principles of insulin formulation and analog design: a century of innovation","volume":"52","author":"Jarosinski","year":"2021","journal-title":"Mol Metab"},{"issue":"10","key":"2025110902541231800_zxaf169-B15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.clinthera.2022.09.003","article-title":"Adherence as a predictor of glycemic control among adolescents with type 1 diabetes: a retrospective study using real-world evidence","volume":"44","author":"Ibrahim","year":"2022","journal-title":"Clin Ther"},{"key":"2025110902541231800_zxaf169-B16"},{"issue":"12","key":"2025110902541231800_zxaf169-B17","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1111\/dom.15973","article-title":"Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China","volume":"26","author":"Hu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025110902541231800_zxaf169-B18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/CEOR.S475461","article-title":"Economic evaluation of once-weekly insulin icodec from Italian NHS perspective","volume":"16","author":"Torre","year":"2024","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025110902541231800_zxaf169-B19","author":"Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services"},{"issue":"4","key":"2025110902541231800_zxaf169-B20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s13668-014-0104-4","article-title":"The intersection between food insecurity and diabetes: a review","volume":"3","author":"Gucciardi","year":"2014","journal-title":"Curr Nutr Rep"},{"key":"2025110902541231800_zxaf169-B21","article-title":"FDA rejects Novo\u2019s once-weekly insulin injection, cites manufacturing process","author":"Manalac","journal-title":"BioSpace"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf169\/63629239\/zxaf169.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/22\/1220\/63629239\/zxaf169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/22\/1220\/63629239\/zxaf169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:54:20Z","timestamp":1762674860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/22\/1220\/8178761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":21,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,11,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf169","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,6,30]]}}}